BRIEF published on 05/16/2024 at 21:10, 1 year 6 months ago 113 Industries Inc. Adopts Four-Day Workweek Enhanced by AI AI Integration Work-life Balance Employee Well-being Four-Day Workweek Innovative Workplace
BRIEF published on 05/16/2024 at 21:10, 1 year 6 months ago 113 Industries Inc. adopte une semaine de travail de quatre jours améliorée par l'IA Intégration De L'IA L'équilibre Travail-vie Bien-être Des Employés Semaine De Travail De Quatre Jours Lieu De Travail Innovant
PRESS RELEASE published on 05/16/2024 at 21:05, 1 year 6 months ago Proprietary AI Helps 113 Industries Inc. Transition to Four-Day Workweek 113 Industries Inc., a leading AI company in Pittsburgh, adopts a four-day workweek to boost employee well-being and productivity. The innovative shift emphasizes work-life balance and dedication to workforce AI Company Work-life Balance Employee Well-being Four-Day Workweek 113 Industries Inc.
Published on 12/05/2025 at 02:35, 4 hours 47 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 22 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 17 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 22 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 22 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 52 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 31 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 57 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 7 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 7 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 22 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 22 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 37 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 37 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
